Related Experiment Videos

Neonatal dexamethasone on day 7 causes mild hyperactivity and cerebellar stunting

S A Ferguson1, R R Holson

  • 1Division of Reproductive & Developmental Toxicology, National Center for Toxicological Research/FDA, Jefferson, AR 72079, USA. sferguson@nctr.fda.gov

Insights

Dexamethasone (DEX) exposure during early development impacts rat brain growth and behavior. Timing of DEX treatment is critical for central nervous system development outcomes.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Pharmacology

Background:

  • Glucocorticoids are crucial for development but can disrupt it.
  • Understanding the impact of synthetic glucocorticoids like dexamethasone (DEX) on the developing central nervous system (CNS) is vital.

Purpose of the Study:

  • To examine how dexamethasone (DEX) administration at different early postnatal days affects CNS development in rats.
  • To assess the long-term consequences of DEX on brain structure and neurobehavioral outcomes.

Main Methods:

  • Rats received DEX (1-3 mg/kg) on postnatal day (PND) 3 or 7.
  • Brain weight, DNA, and protein content were analyzed at various time points (PND 28, 84, 112).
  • Neurobehavioral tests included nest odor preference, open field activity, running wheel activity, and maze performance.

Main Results:

  • DEX treatment on PND 7 reduced brain and regional weights by PND 28, with partial recovery by PND 112.
  • Hyperactivity was observed in rats treated with DEX on PND 7.
  • Cerebellar and hippocampal development showed sensitivity to DEX exposure, with effects varying by treatment timing.

Conclusions:

  • The timing of glucocorticoid exposure significantly influences the severity of CNS insults during development.
  • Early-life DEX exposure can lead to lasting neurodevelopmental and behavioral changes.
  • These findings highlight the critical developmental windows for brain vulnerability to glucocorticoids.

Related Concept Videos